SCHEDULE: TD Bank Discloses 5.8% Stake in Stoke Therapeutics

The Toronto-Dominion Bank has reported a 5.8% beneficial ownership stake in Stoke Therapeutics, Inc., holding 3,173,258 shares of common stock.

Summary

• The Toronto-Dominion Bank (TD Bank) has filed a Schedule 13G, disclosing beneficial ownership of 3,173,258 shares of common stock in Stoke Therapeutics, Inc.
• This represents a 5.8% stake in the company's common stock.
• TD Bank holds sole voting power and sole dispositive power over all 3,173,258 shares.
• The event requiring this filing, where TD Bank crossed the 5% ownership threshold, occurred on September 30, 2025.
• The beneficial ownership was transferred to TD Bank from Cowen Financial Products LLC, an affiliated entity, between the event date and the filing date.
• TD Bank certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Stoke Therapeutics.

Sentiment

Score: 6

Explanation: The filing is a standard beneficial ownership disclosure by a major financial institution, indicating a significant stake in Stoke Therapeutics. While generally neutral, the acquisition of a 5.8% stake by The Toronto-Dominion Bank can be viewed as a positive signal of institutional interest and confidence in the company.

Positives

• A major financial institution, The Toronto-Dominion Bank, has taken a significant 5.8% stake in Stoke Therapeutics, indicating institutional confidence or interest.
• The acquisition was made in the ordinary course of business, suggesting a strategic investment rather than an activist play.

Negatives

• No specific negative information is disclosed in this beneficial ownership filing.

Risks

• No specific risks related to Stoke Therapeutics, Inc. are disclosed in this beneficial ownership filing.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

The acquisition of a significant stake by a major bank like The Toronto-Dominion Bank in a biotechnology company such as Stoke Therapeutics can signal growing institutional interest in the life sciences sector, particularly in companies with promising therapeutic pipelines. This type of investment often reflects a long-term view on the company's potential within its specific therapeutic area.

Comparison to Industry Standards

• A 5.8% stake by a large financial institution like TD Bank is a notable position, often seen as a vote of confidence in the underlying company's long-term prospects, similar to other institutional investments in emerging biotech firms.
• While not directly comparable to specific project results, the beneficial ownership by a major bank aligns with trends where large financial entities diversify their portfolios with strategic investments in growth sectors like biotechnology, often alongside other institutional investors such as BlackRock or Vanguard who frequently disclose similar passive stakes.

Related Party Transactions

• Beneficial ownership of the subject securities was transferred by Cowen Financial Products LLC, an affiliated entity, to The Toronto-Dominion Bank.

Stakeholder Impact

• Shareholders may view the significant stake by The Toronto-Dominion Bank as a positive indicator of institutional confidence in Stoke Therapeutics, potentially influencing market perception.
• The filing indicates a passive investment, suggesting no immediate impact on the company's strategic direction or control.

Next Steps

• The Toronto-Dominion Bank will continue to monitor its investment in Stoke Therapeutics, Inc. and may file amendments to this Schedule 13G if its beneficial ownership materially changes.

Key Dates

Recommendation

The filing indicates a significant institutional investment by The Toronto-Dominion Bank, which can be a positive signal of confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide fundamental financial or operational details about Stoke Therapeutics. Without further information on the company's performance, pipeline, or market position, a 'hold' recommendation is prudent, acknowledging the institutional interest while awaiting more comprehensive data for a stronger conviction.

Keywords

Stoke Therapeutics, TD Bank, Toronto-Dominion Bank, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Financial Services